1 / 18
EURAMOS 1. A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy. Jeremy Whelan for the EURAMOS 1 Trial Management Group, 4 th November 2006. EURAMOS.
Presentation posted in :
An Image/Link below is provided (as is) to download presentation
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other sites. SlideServe reserves the right to change this policy at anytime.
While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy
Jeremy Whelan for the EURAMOS 1 Trial Management Group, 4th November 2006
EURAMOS EURAMOS is the European and American Osteosarcoma Study Group. The study was founded in 2001. Children’s Oncology Group Cooperative Osteosarcoma Study Group European Osteosarcoma Intergroup Scandinavian Sarcoma Group EURAMOS Established Oct 2001 Aim to improve survival from OS Objectives to carry out large international randomised trials to facilitate biological research to seek new therapeutic approaches to develop common understanding and methodologies for staging, pathology etc. EURAMOS 1 Co-sponsored MRC in Europe COG for North America Co-ordinating Data Centre Trial Design Key registration criteria High grade OS of extremity or axial skeleton Resectable disease Fit for treatment Trial Design Key randomisation criteria Adequate pre-operative chemotherapy Macroscopically complete resection of primary tumour Complete removal of all metastases or complete removal planned and feasible Histological response assessment Trial Design Primary Objectives Addition of IE to post-op MAP chemotherapy improves EFS for poor responders Addition of ifn to post-op MAP chemotherapy improves EFS for good responders Trial Design Secondary Objectives Additional treatment improves OS, short and long term toxicity and quality of life Additional treatment improves EFS in localised disease Investigate biological and clinical correlated to histological response and outcome International cooperation in trials Examine outcome of the entire cohort of patients Trial Design- additional studies Quality of Life Biology Studies Progress: open and recruiting Progress: requests to join Czech Republic Ireland Poland Israel EURAMOS 1 Chief Investigators Mark Bernstein (TMG Chair) Neyssa Marina (COG) Stephan Bielack (COSS) Jeremy Whelan (EOI) Sigbjorn Smeland (SSG) Website